A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma
Latest Information Update: 16 Jun 2024
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 01 Jun 2024 Results reporting safety and efficacy data with median follow-up of over 5years published in the Leukemia and Lymphoma
- 14 Sep 2022 Status changed from active, no longer recruiting to discontinued.
- 08 Jan 2021 Planned End Date changed from 12 Sep 2020 to 31 Jul 2024.